Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

TAS-102 in Third or Fourth Line for mCRC

February 1st 2021

Experts in mCRC review data on TAS-102 and discuss how best to sequence therapies in the third or fourth line.

Regorafenib in Third or Fourth Line for mCRC: Safety in the Re-DOS Trial

February 1st 2021

Axel Grothey, MD, and John Marshall, MD, discuss safety results from the ReDOS study of regorafenib in patients with mCRC.

Regorafenib in Third or Fourth Line for mCRC: Efficacy in the Re-DOS Trial

February 1st 2021

John Marshall, MD, reviews efficacy data from the ReDOS study of regorafenib in patients with mCRC.

Therapy After Progression in mCRC

February 1st 2021

Experts in metastatic colorectal cancer review therapeutic options after progression for patients with mCRC.

Maintenance or Chemo-Free Interval in mCRC

January 29th 2021

Experts in metastatic colorectal cancer discuss when and in which patients to use a chemotherapy-free treatment interval.

Optimizing First-Line Therapy in mCRC

January 29th 2021

Axel Grothey, MD, and John Marshall, MD, discuss strategies for optimizing first-line treatment in metastatic colorectal cancer and the role of adjuvant therapy.

Onvansertib Plus FOLFIRI/Bevacizumab Shows Preliminary Efficacy, Tolerability in Second-Line mCRC

January 27th 2021

January 27, 2021 - The combination of the polo-like kinase 1 inhibitor, onvansertib, with FOLFIRI and bevacizumab was found to have preliminary activity and favorable tolerability when used as a second-line treatment for patients with KRAS-mutated metastatic colorectal cancer.

Dr. Raghav on Sequencing Therapies for Resectable Versus Unresectable CRC

January 26th 2021

Kanwal Raghav, MBBS, MD, discusses his approach to sequencing therapies for patients with resectable and unresectable colorectal cancer.

Postoperative MRD Positivity Linked With Reduced RFS in CRC

January 26th 2021

January 26, 2021 — Patients with colorectal cancer who had molecular residual disease positivity immediately after surgery were found to have a high risk of disease recurrence and longitudinal monitoring increased the predictive power of circulating tumor DNA.

Frontline Pembrolizumab Approved in Europe for Metastatic MSI-H/dMMR CRC

January 26th 2021

January 26, 2021 - The European Commission has approved single-agent pembrolizumab for use in the frontline treatment of patients with metastatic microsatellite instability–high or mismatch repair deficient colorectal cancer.

Dr. Marshall on Changes With Adjuvant Treatment in CRC

January 25th 2021

John L. Marshall, MD, discusses recent changes to the adjuvant treatment landscape in colorectal cancer.

Dr. Strickler on Dosing Regorafenib in CRC

January 25th 2021

John H. Strickler, MD, discusses dosing strategies with regorafenib in colorectal cancer.

Dr. Dasari on the Potential Clinical Implications of Fruquintinib in mCRC

January 25th 2021

Nageshwara Arvind Dasari, MD, discusses the potential clinical implications with fruquintinib in metastatic colorectal cancer.

Big Data Tool Finds Variations in Treatment and Costs Across 3 Cancer Types

January 25th 2021

Using real-world data from more than 4000 patients with common cancers, an algorithm was able to detect variations in care that, if reduced, could result in a median savings of $26,773 per patient.

Dr. Hubbard on Sequencing Challenges With EGFR Inhibitors in CRC

January 22nd 2021

Joleen M. Hubbard, MD, discusses sequencing challenges regarding EGFR inhibitors in colorectal cancer.

Dr. Bekaii-Saab Discusses Indicators of Progression in CRC

January 22nd 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses indicators of progression in colorectal cancer.

First-Line Options in mCRC

January 22nd 2021

Axel Grothey, MD, and John Marshall, MD, discuss first-line treatment options in patients with metastatic colorectal cancer.

Treatment Considerations in mCRC

January 22nd 2021

Axel Grothey, MD, discusses factors that influence treatment selection in patients with mCRC.

Dr. Ahn on the Growing Role of ctDNA as a Biomarker in CRC

January 21st 2021

Daniel H. Ahn, DO, discusses the growing role of circulating tumor DNA in colorectal cancer.

Dr. Lwin on Patient Selection for LEAP-005 Study in CRC, Biliary Tract Cancer, and More

January 20th 2021

Zarnie Lwin, MBBS, FRACP, discusses patient selection, including those with colorectal cancer, for the phase 2 LEAP-005 study.